Items Tagged ‘nsclc’

October 4th, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq


September 21st, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine


July 6th, 2017

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

By

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone, […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, News, nivolumab, nsclc, opdivo, Precision Cancer Medicine


June 12th, 2017

Alecensa Superior to Xalkori in Treatment of Lung Cancer

By

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Both drugs are designed to treat advanced non-small cell lung cancer (NSCLC) in […]

View full entry

Tags: Alecensa, alectinib, ALK gene, ALK-positive NSCLC, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, xalkori


May 30th, 2017

Imfinzi Improves Outcomes for Patients With Stage III Non Small Cell Lung Cancer

By

Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy have been reported.1 Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, […]

View full entry

Tags: durvalumab, Imfinzi, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, Stage III non-small cell lung cancer


May 11th, 2017

FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 precision cancer medicine, in combination with Alimta®  (pemetrexed) and carboplatin chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for […]

View full entry

Tags: keytruda, Lung Cancer, News, nsclc, PD-1, precision cancer immunotherapy


April 18th, 2017

Tagrisso Approved for Treatment of Certain Lung Cancers

By

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Lung cancer remains the leading […]

View full entry

Tags: immunotherapy, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, tagrisso


April 13th, 2017

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer

By

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual Meeting in Washington DC this week. Lung cancer remains the leading cause of cancer-related deaths in the […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, Precision Medicine PD-1


March 7th, 2017

Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC

By

The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The FDA also granted Breakthrough Therapy designation to Zykadia for the first-line […]

View full entry

Tags: Alk 1, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Zykadia® ceritinib


December 19th, 2016

Tagrisso®: New Standard of Care for Certain Lung Cancer

By

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed following prior therapy with an epidermal growth factor receptor (EGFR) inhibitor. Lung cancer remains the leading cause of cancer-related deaths in the […]

View full entry

Tags: EGFR, epidermal growth factor receptor, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, osimertinib, Stages IIIB-IV Lung Cancer - Non-Small Cell, T790 mutation, tagrisso


November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 25th, 2016

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such as Keytruda […]

View full entry

Tags: fda, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab